Stock Track | CytomX Therapeutics Plummets 7.80% as Analysts Slash Revenue and Earnings Forecasts

Stock Track11-13

CytomX Therapeutics (NASDAQ:CTMX) saw its stock plummet by 7.80% in pre-market trading on Thursday, following a substantial negative revision to the company's forecasts by analysts. The dramatic downgrade has raised serious concerns about the biotech firm's future performance and financial outlook.

According to the latest analyst reports, CytomX Therapeutics is now expected to face a significant decline in revenues and potentially slip into loss-making territory. Analysts have revised their 2026 revenue forecasts downwards from US$50 million to US$31 million, representing a painful 73% decline in sales compared to the previous year. Additionally, earnings per share (EPS) forecasts have been adjusted, with analysts now predicting losses of US$0.40 per share in 2026, compared to the earlier estimate of US$0.27 per share loss.

The downgrade paints a grim picture for CytomX Therapeutics' growth trajectory. While the broader industry is anticipated to see revenue growth of 22% annually for the foreseeable future, CytomX is expected to experience a significant contraction. This pessimistic outlook has clearly spooked investors, resulting in the pre-market plunge as traders reassess their positions in light of the company's challenging future. Despite the gloomy forecast, analysts have surprisingly lifted their price target by 15% to US$7.07, adding an element of confusion to the market's interpretation of CytomX's prospects.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1185608041?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-13 22:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1185608041","market":"nz","top_or_hot":-1,"title":"Stock Track | CytomX Therapeutics Plummets 7.80% as Analysts Slash Revenue and Earnings Forecasts","media":"Stock Track","content":"<p>CytomX Therapeutics (NASDAQ:CTMX) saw its stock plummet by 7.80% in pre-market trading on Thursday, following a substantial negative revision to the company's forecasts by analysts. The dramatic downgrade has raised serious concerns about the biotech firm's future performance and financial outlook.</p>\n\n<p>According to the latest analyst reports, CytomX Therapeutics is now expected to face a significant decline in revenues and potentially slip into loss-making territory. Analysts have revised their 2026 revenue forecasts downwards from US$50 million to US$31 million, representing a painful 73% decline in sales compared to the previous year. Additionally, earnings per share (EPS) forecasts have been adjusted, with analysts now predicting losses of US$0.40 per share in 2026, compared to the earlier estimate of US$0.27 per share loss.</p>\n\n<p>The downgrade paints a grim picture for CytomX Therapeutics' growth trajectory. While the broader industry is anticipated to see revenue growth of 22% annually for the foreseeable future, CytomX is expected to experience a significant contraction. This pessimistic outlook has clearly spooked investors, resulting in the pre-market plunge as traders reassess their positions in light of the company's challenging future. Despite the gloomy forecast, analysts have surprisingly lifted their price target by 15% to US$7.07, adding an element of confusion to the market's interpretation of CytomX's prospects.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | CytomX Therapeutics Plummets 7.80% as Analysts Slash Revenue and Earnings Forecasts</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | CytomX Therapeutics Plummets 7.80% as Analysts Slash Revenue and Earnings Forecasts\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-13 22:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CytomX Therapeutics (NASDAQ:CTMX) saw its stock plummet by 7.80% in pre-market trading on Thursday, following a substantial negative revision to the company's forecasts by analysts. The dramatic downgrade has raised serious concerns about the biotech firm's future performance and financial outlook.</p>\n\n<p>According to the latest analyst reports, CytomX Therapeutics is now expected to face a significant decline in revenues and potentially slip into loss-making territory. Analysts have revised their 2026 revenue forecasts downwards from US$50 million to US$31 million, representing a painful 73% decline in sales compared to the previous year. Additionally, earnings per share (EPS) forecasts have been adjusted, with analysts now predicting losses of US$0.40 per share in 2026, compared to the earlier estimate of US$0.27 per share loss.</p>\n\n<p>The downgrade paints a grim picture for CytomX Therapeutics' growth trajectory. While the broader industry is anticipated to see revenue growth of 22% annually for the foreseeable future, CytomX is expected to experience a significant contraction. This pessimistic outlook has clearly spooked investors, resulting in the pre-market plunge as traders reassess their positions in light of the company's challenging future. Despite the gloomy forecast, analysts have surprisingly lifted their price target by 15% to US$7.07, adding an element of confusion to the market's interpretation of CytomX's prospects.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CTMX","symbol_name":"CytomX","start_time":0,"source_url":"","article_id":"1185608041","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1185608041","pubTimestamp":1763044596,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"CytomX Therapeutics (NASDAQ:CTMX) saw its stock plummet by 7.80% in pre-market trading on Thursday, following a substantial negative revision to the company's forecasts by analysts. The dramatic...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CTMX":"CytomX"},"translate_title":"个股追踪|分析师大幅下调营收和盈利预期，CytomX Therapeutics暴跌7.80%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CTMX":1},"content_text":"CytomX Therapeutics (NASDAQ:CTMX) saw its stock plummet by 7.80% in pre-market trading on Thursday, following a substantial negative revision to the company's forecasts by analysts. The dramatic downgrade has raised serious concerns about the biotech firm's future performance and financial outlook.\nAccording to the latest analyst reports, CytomX Therapeutics is now expected to face a significant decline in revenues and potentially slip into loss-making territory. Analysts have revised their 2026 revenue forecasts downwards from US$50 million to US$31 million, representing a painful 73% decline in sales compared to the previous year. Additionally, earnings per share (EPS) forecasts have been adjusted, with analysts now predicting losses of US$0.40 per share in 2026, compared to the earlier estimate of US$0.27 per share loss.\nThe downgrade paints a grim picture for CytomX Therapeutics' growth trajectory. While the broader industry is anticipated to see revenue growth of 22% annually for the foreseeable future, CytomX is expected to experience a significant contraction. This pessimistic outlook has clearly spooked investors, resulting in the pre-market plunge as traders reassess their positions in light of the company's challenging future. Despite the gloomy forecast, analysts have surprisingly lifted their price target by 15% to US$7.07, adding an element of confusion to the market's interpretation of CytomX's prospects.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1185608041","isCrawlerRequest":true}